Ditchcarbon
  • Contact
  1. Organizations
  2. Novartis
Public Profile
Pharmaceutical Preparation Manufacturing
CH
updated 15 days ago

Novartis

Company website

Novartis AG, a leading global healthcare company headquartered in Switzerland (CH), has established itself as a pioneer in the pharmaceutical industry since its founding in 1996. With a strong presence in key operational regions including North America, Europe, and Asia, Novartis focuses on innovative medicines, generics, and eye care products. The company is renowned for its commitment to research and development, producing unique therapies in areas such as oncology, cardiology, and immunology. Notable achievements include the development of groundbreaking treatments that have transformed patient care. As a top player in the pharmaceutical market, Novartis continues to drive advancements in healthcare, making significant contributions to global health and well-being.

DitchCarbon Score

How does Novartis's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

100

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

33

Industry Benchmark

Novartis's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.

100%

Let us know if this data was useful to you

Novartis's reported carbon emissions

In 2024, Novartis reported total carbon emissions of approximately 4,587,300,000 kg CO2e, with Scope 1 emissions at about 2,070,000,000 kg CO2e, Scope 2 emissions at approximately 2,004,000,000 kg CO2e, and Scope 3 emissions significantly higher at around 43,503,000,000 kg CO2e. This reflects a commitment to reducing its carbon footprint across all scopes, with a target to achieve carbon neutrality in its own operations (Scope 1 and 2) by 2025. Novartis has set ambitious reduction targets, aiming for a 90% reduction in absolute Scope 1 and 2 emissions by 2030 from a 2022 baseline, and a 42% reduction in absolute Scope 3 emissions within the same timeframe. Additionally, the company is committed to achieving net-zero greenhouse gas emissions across its value chain by 2040. The company has made significant progress, having reduced its Scope 1 and 2 emissions by 19% year-on-year, amounting to a total reduction of 63% compared to its 2016 baseline. These targets are aligned with the Science Based Targets initiative (SBTi) and are consistent with the goals of the Paris Agreement to limit global temperature rise to 1.5°C. Novartis's climate commitments are part of a broader strategy to integrate environmental sustainability into its operations, reflecting its understanding of the interrelationship between planetary and human health.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

201020112012201320142015201620172018201920202021202220232024
Scope 1
583,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
00,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
Scope 2
922,000,000
0,000,000,000
0,000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
00,000,000
00,000,000
Scope 3
-
-
000,000,000
000,000,000
000,000,000
000,000,000
-
000,000,000
000,000,000
000,000,000
0,000,000,000
0,000,000,000
00,000,000,000
00,000,000,000
00,000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Novartis's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Novartis is in CH, which has a very low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Novartis is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

GlaxoSmithKline Pharmaceuticals Limited

IN
•
Pharmaceutical Preparation Manufacturing
Updated about 8 hours ago

Pfizer

US
•
Pharmaceutical Preparation Manufacturing
Updated about 8 hours ago

Abbvie

US
•
Pharmaceutical Preparation Manufacturing
Updated 38 minutes ago

Merck And Co

US
•
Pharmaceutical Preparation Manufacturing
Updated 5 days ago

Biogen

US
•
Pharmaceutical Preparation Manufacturing
Updated 37 minutes ago

Bristol-Myers Squibb

US
•
Pharmaceutical Preparation Manufacturing
Updated 38 minutes ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251016.4
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy